Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
| IAD | Amended Form 2A - 31 December 2017 - Goodwill and Intangibles amended (Price Sensitive) | PRICE SENSITIVE | 17/04/18 | |
| IAD | Half Yearly Report - 31 December 2017 (Price Sensitive) | PRICE SENSITIVE | 09/03/18 | |
| IAD | Half Yearly Financial Statements - 31 December 2017 (Price Sensitive) | PRICE SENSITIVE | 09/03/18 | |
| IAD | Director's Declaration - Dirk Holwerda | 09/03/18 | ||
| IAD | Director's Declaration - Kerralie Shaw | 09/03/18 | ||
| IAD Amended Form 2A - 31 December 2017 - Goodwill and Intangibles amended (Price Sensitive) | |||
| 17/04/18 | PRICE SENSITIVE | ||
| IAD Half Yearly Report - 31 December 2017 (Price Sensitive) | |||
| 09/03/18 | PRICE SENSITIVE | ||
| IAD Half Yearly Financial Statements - 31 December 2017 (Price Sensitive) | |||
| 09/03/18 | PRICE SENSITIVE | ||
| IAD Director's Declaration - Dirk Holwerda | |||
| 09/03/18 | |||
| IAD Director's Declaration - Kerralie Shaw | |||
| 09/03/18 | |||
